Bloomsbury Genetic Therapies launches with Seed financing of £5 million to develop potentially curative gene therapy treatments for rare neurological and metabolic diseasesLondon, UK, 7 October 2022 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a biotechnology company developin.
Arcturus is gearing up to begin a phase 2 study using ARCT-810 for the treatment of patients with a rare disease known as OTC deficiency. Click to read more.
The "Ornithine Transcarbamylase Deficiency (OTC Deficiency) Epidemiology Forecast 2032" report has been added to ResearchAndMarkets.com's offering. The Ornithine Transcarbamylase Deficiency (OTC Deficiency)
Global Genes Through the Eyes of a Patient - Cox Scholarship Winner, Natalie Morris - By Natalie Morris, Medical Student at Cooper Medical School of Rowan University in New Jersey and winner of 2021 Cox ScholarshipNo one in my family has a rare disease. I come from a family that suffers from the common ailments of the Western world. My father died when I was 15 from a heart attack, and I have spent the years thereafter turning my family into their healthiest selves.